4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have received an average recommendation of "Moderate Buy" from the nine ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $45.25.

FDMT has been the subject of a number of research reports. Chardan Capital lifted their target price on shares of 4D Molecular Therapeutics from $38.00 to $39.00 and gave the company a "buy" rating in a research note on Thursday, September 19th. Leerink Partners reissued an "outperform" rating and set a $36.00 price objective (down previously from $40.00) on shares of 4D Molecular Therapeutics in a research report on Thursday, September 19th. Cantor Fitzgerald lowered 4D Molecular Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Monday, September 23rd. Royal Bank of Canada reaffirmed an "outperform" rating and set a $40.00 price target on shares of 4D Molecular Therapeutics in a research note on Monday, July 22nd. Finally, BMO Capital Markets lowered their price target on 4D Molecular Therapeutics from $63.00 to $40.00 and set an "outperform" rating for the company in a research note on Thursday, July 18th.

4D Molecular Therapeutics Trading Up 0.9 %

NASDAQ FDMT traded up $0.08 during trading on Friday, reaching $8.53. 1,024,523 shares of the company's stock were exchanged, compared to its average volume of 901,888. 4D Molecular Therapeutics has a fifty-two week low of $8.37 and a fifty-two week high of $36.25. The company's fifty day simple moving average is $13.03 and its 200-day simple moving average is $19.63. The firm has a market capitalization of $441.03 million, a PE ratio of -3.50 and a beta of 2.77.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.09. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $1.90 million. Equities analysts forecast that 4D Molecular Therapeutics will post -2.74 EPS for the current fiscal year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. nVerses Capital LLC bought a new position in shares of 4D Molecular Therapeutics in the third quarter valued at approximately $40,000. SG Americas Securities LLC acquired a new position in 4D Molecular Therapeutics in the 3rd quarter valued at $321,000. Healthcare of Ontario Pension Plan Trust Fund lifted its position in 4D Molecular Therapeutics by 10.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 706,000 shares of the company's stock worth $14,819,000 after acquiring an additional 65,000 shares during the last quarter. Algert Global LLC lifted its position in 4D Molecular Therapeutics by 20.6% during the 2nd quarter. Algert Global LLC now owns 16,588 shares of the company's stock worth $348,000 after acquiring an additional 2,828 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in 4D Molecular Therapeutics by 25.5% during the second quarter. The Manufacturers Life Insurance Company now owns 18,975 shares of the company's stock valued at $398,000 after acquiring an additional 3,850 shares during the period. Institutional investors own 99.27% of the company's stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.